PATENT CLAIM ANALYSIS

Application Number: 16322936
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["536", "026800"]

Abstract:
A gemcitabine ProTide hypoxic-activated prodrug and a use thereof in the preparation of a medicament for treating tumors. The general structural formula thereof is formula (A), wherein: one of R1 and R2 is a hypoxic-activated group of —C(R3R4)ArNO2, and the other is an alkyl group of 1 to 6 carbon atoms, a phenyl group or —CH2Ar, wherein R3 and R4 are —H or a methyl group, and —Ar is an aromatic ring compound. The gemcitabine ProTide hypoxic-activated prodrug described in the present invention has a stronger cytotoxicity under a hypoxic condition, has excellent anti-tumor effects and is very safe; the present invention can be used along with other anti-tumor drugs to exert a better anti-tumor activity, and can be used in the preparation of a medicament for treating tumors.

Claim (Index 17):
The method of  claim 8 , wherein R 1  is a phenyl group, a structure of R 2  is: R 3  is \u2014H or a methyl group, and R 4  is a methyl group.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 99.0
- Lexical Diversity: 1.86076
- Patent Class: 536.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13695804', '15547013', '12077729', '11244427', '13696425']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6184834884352441
- 35 USC 102 Novelty (BERT): 0.4964029258631256
- Combined Prediction Score: 0.6062754321780323
- Mean Citation Score: 248.44587
- Max Citation Score: 254.3387
- Similarity Product: 205.07501806986923

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test